First-Ever Stem Cell GMP Warning Letter Cites IntelliCell
This article was originally published in The Pink Sheet Daily
FDA finds the company failed to establish procedures for a range of GMP basics, which is a problem because according to the agency the IntelliCell adipose tissue-derived stem cells are both a drug and a biologic product.
You may also be interested in...
FDA tells Celltex Therapeutics that its stem cell treatments are to be regulated as biologics; company contends they should be considered a human cell and tissue product.
The letter details problems related to Baxter's use of albumin in the manufacturing of its Isolex 300i Magnetic Cell Selection System, a device/biologic regulated as a Class III device.
Less than a year after signing a consent decree to resolve compliance problems, the company is forced to stop manufacturing its generic version of the best-selling cholesterol drug. For FDA, the issue poses a public relations challenge since it touches on several areas where the agency has recently been criticized – generic drug quality, manufacturing oversight and drug shortages.